Befejeződött1. fázis
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
Key facts
- Where
- Lille, Montpellier Cedex 5, Nantes, Paris, Pierre-Bénite, Rennes és Rouen Cedex, FranciaországSee the 7 sites
- Phase
- 1. fázis
Where in Franciaország
- Centre Hospitalier Universitaire de LilleLille, FranciaországNo longer taking part
- Centre Hospitalier Universitaire De MontpellierMontpellier Cedex 5, FranciaországNo longer taking part
- Centre Hospitalier Universitaire de NantesNantes, FranciaországNo longer taking part
- Hopital Saint LouisParis, FranciaországNo longer taking part
- Centre Hospitalier Lyon-SudPierre-Bénite, FranciaországNo longer taking part
- Centre Hospitalier Universitaire de RennesRennes, FranciaországNo longer taking part
- Centre Henri BecquerelRouen Cedex, FranciaországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- F. Hoffmann-La Roche AG
- Trial code
- EU 2023-507497-40-00
- Record updated
- 2024. május 16.